In this new Trade To Black Podcast, TDR Founder Shadd Dales interviews the CEO of Lobe Sciences (OTC: LOBEF), Philip Young. Lobe Sciences is an emerging psychedelic biotech company developing psilocin and nontraditional medicines for better brain health.

While psilocybin gets all the attention in the psychedelics industry, psilocybin is actually not bioactive on its own and must be converted into psilocin through a process called dephosphorylation to take effect. Psilocin is psychoactive but not stable, as it degrades quickly in the presence of air, heat, and light. The issue of molecule stability is why most psychedelic companies continue to work with psilocybin, despite its increased cost.

Enter Lobe Sciences, which after at least ten months of research development, appears to have solved the issue of …

Full story available on Benzinga.com